7 min read
When the FDA’s Quality Management System Regulation became effective on February 2, 2026, most of the medical device industry treated it as a compliance milestone. Procedures needed to be updated. Quality manuals needed to be revised. Teams needed to be trained. QMSR inspection readiness plans needed to be rebuilt around the new expectations under 21 CFR Part 820 QMSR.
That work is necessary. But it is not the full story.
The deeper significance of QMSR is that the FDA has formally moved the U.S. medical device quality system closer to the global language of medical device regulation by incorporating ISO 13485:2016 by reference. For device manufacturers, this is more than a regulatory update. It is a strategic opening.
QMSR gives medical device companies a more harmonized foundation for building, defending, and scaling clinical evidence across markets. For manufacturers operating in the United States, Latin America, and other international jurisdictions, the new regulation changes the conversation from “How do we comply?” to “How do we use quality alignment to strengthen our QMSR global regulatory strategy?”
The industry is focused on compliance. Leaders should be focused on leverage.
The initial industry response to QMSR has been predictable. Most companies are asking operational questions: What procedures need to change? How will FDA inspections evolve? What terminology must be revised? How should gaps against ISO 13485 be documented?
Those questions matter. The FDA’s own QMSR frequently asked questions make clear that manufacturers must understand how the new regulation interacts with FDA-specific requirements. QMSR does not simply U.S. device quality regulation to ISO. FDA authority remains intact, and where applicable U.S. statutory or regulatory requirements apply, they continue to control.
But a purely compliance-driven view is incomplete.
The strategic value of the QSR to QMSR transition is that it reduces the quality-system disconnect that historically existed between the U.S. device framework and the international quality infrastructure used by many regulators outside the United States. In practical terms, sponsors can now build a more coherent narrative around the quality management system for medical devices across manufacturing, clinical operations, regulatory submissions, and post-market obligations.
That matters because regulators do not review clinical evidence in isolation. They review the system behind the evidence.
International clinical data needs more than a good protocol
The FDA already provides a pathway for using clinical data from investigations conducted outside the United States to support device applications and submissions. Its guidance on the acceptance of clinical data to support medical device applications and submissions emphasizes that outside-U.S. clinical investigations must meet applicable expectations for good clinical practice, including independent ethics committee review and informed consent.
This is a critical point. QMSR does not automatically make international clinical data acceptable. A poorly designed or poorly monitored study does not become persuasive because the sponsor has an ISO 13485-aligned quality system.
However, QMSR does help sponsors connect the clinical evidence package to a stronger and more globally recognized quality foundation. That connection is especially important when data are generated across multiple jurisdictions.
A well-designed international evidence strategy should now ask: Was the device developed under a quality system aligned with FDA expectations? Were clinical activities governed with appropriate oversight? Were sites qualified properly? Were risks controlled and documented? Is there traceability between design controls, risk management, clinical endpoints, adverse event handling, and the final regulatory claim?
In the post-QMSR environment, those questions become easier to answer when the sponsor has built its development program around QMSR ISO 13485 harmonization and a quality architecture from the beginning.
Latin America should be viewed through the lens of quality maturity
Latin America is often discussed in medical device development as a region of operational advantage. Sponsors point to patient access, recruitment potential, physician expertise, and market diversity. Those are important considerations, but they should not be the center of the regulatory argument.
The stronger argument is quality maturity.
Brazil’s regulator, ANVISA, participates in the Medical Device Single Audit Program, and ANVISA describes MDSAP as a program designed to reduce duplication of regulatory effort while supporting alignment around international standards and good practices. Mexico’s COFEPRIS also identifies medical device regulatory convergence through the International Medical Device Regulators Forum, reinforcing the broader movement toward international harmonization.
This does not mean every site, CRO, investigator, or manufacturer in Latin America is automatically suitable for a global device program. They are not. The same due diligence required in the United States or Europe must be applied locally.
But it does mean that Latin America medical device clinical trial planning should not be viewed merely as a lower-cost clinical region. For well-prepared sponsors, it can be positioned as part of a broader global evidence strategy supported by internationally recognized quality principles.
That is where QMSR changes the strategic calculus.
MDSAP becomes more important after QMSR
The Medical Device Single Audit Program was created to allow a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer’s quality management system that can satisfy the requirements of multiple participating regulatory authorities.
Historically, many manufacturers viewed MDSAP as an audit-efficiency tool. It reduced duplication. It helped support access to multiple markets. It made quality oversight more scalable.
After QMSR, MDSAP should be viewed more strategically.
Because FDA’s quality system regulation is now anchored to ISO 13485, reflecting 21 CFR Part 820 ISO 13485 alignment, an MDSAP-audited quality system can help create a more integrated regulatory story. The sponsor’s QMS, manufacturing controls, supplier oversight, risk management process, clinical evidence generation, and international market strategy can be presented through a more consistent quality language.
This can be especially valuable for companies pursuing U.S. submissions while also planning commercialization or clinical activity in markets such as Brazil, Mexico, Canada, Japan, and Australia.
The benefit is not that an MDSAP audit for a medical device manufacturer replaces FDA review. It does not. The benefit is that MDSAP can strengthen the sponsor’s ability to demonstrate quality-system maturity across jurisdictions.
The real ROI of QMSR is regulatory credibility
Many companies will measure QMSR readiness by whether they can pass an inspection. That is a minimum expectation, not a competitive advantage.
The more meaningful return is regulatory credibility.
A company with a mature QMSR-aligned system can tell a stronger story about how its device was designed, manufactured, tested, clinically evaluated, and controlled across the product lifecycle. That story matters in FDA interactions. It matters in due diligence. It matters in global registrations. It matters when regulators ask whether the data supporting a device are reliable, traceable, and relevant.
This is particularly important for companies using international clinical data.
The FDA’s framework for acceptance of data from clinical investigations for medical devices is built around quality, integrity, and protection of human subjects. QMSR gives sponsors an opportunity to align the quality system behind the device with the quality expectations behind the data.
That alignment should not be treated as a submission afterthought. It should be designed into the program before the first subject is enrolled.
A practical framework for Medical Device companies
Medical device companies that want to move beyond basic QMSR compliance should begin by treating QMSR compliance strategy as part of their full development strategy and mapping their quality system accordingly.
The first question is whether the organization’s QMS can support the intended regulatory pathway. A 510(k), De Novo, PMA, or IDE strategy will each place different demands on design history, risk management, clinical evidence, supplier control, complaint handling, CAPA, post-market surveillance, and the QMSR impact on 510(k) and PMA submissions.
The second question is whether the company’s international evidence strategy is quality-led. If clinical work is being considered in Latin America or any other outside-U.S. market, the sponsor should evaluate site qualification, investigator experience, ethics committee oversight, monitoring processes, adverse event reporting, data integrity systems, and documentation controls.
The third question is whether MDSAP can strengthen the company’s global regulatory position. For manufacturers targeting multiple jurisdictions, MDSAP may support a more efficient and more credible quality narrative.
The fourth question is whether the submission strategy explains the quality architecture clearly. FDA reviewers should not have to infer why international clinical data are reliable. The sponsor should proactively connect the dots between QMSR alignment, ISO 13485-based controls, clinical governance, and the intended regulatory claim.
QMSR is part of a larger harmonization movement
QMSR should not be seen as an isolated U.S. regulatory event, but as part of medical device regulatory convergence. It is part of a broader global movement toward medical device regulatory convergence.
The International Medical Device Regulators Forum exists to accelerate international harmonization and convergence in medical device regulation. Its work on areas such as MDSAP and regulatory reliance reflects a clear direction of travel: regulators are seeking more consistent ways to evaluate quality, safety, performance, and oversight across jurisdictions.
The IMDRF’s recent Playbook for Medical Device Regulatory Reliance Programs further reinforces the global importance of reliance, convergence, and efficient regulatory decision-making.
For medical device manufacturers, this trend has a practical implication. Quality systems can no longer be managed as local compliance silos. They must be designed as global operating systems.
The companies that win will use QMSR strategically
FDA QMSR has created a new baseline for FDA quality system regulation 21 CFR Part 820 in the United States. Every manufacturer must respond to that baseline.
But not every manufacturer will extract the same value from it.
Some companies will update their SOPs, retrain their teams, and prepare for inspection. That is necessary, but it is defensive.
The more forward-looking companies will use QMSR to rethink how quality, clinical evidence, and global regulatory strategy fit together. They will use ISO 13485 FDA alignment to strengthen international development plans. They will evaluate MDSAP not only as an audit pathway, but as a strategic credibility tool. They will approach Latin America and other international markets not merely as operational alternatives, but as components of a globally harmonized evidence strategy.
The QMSR deadline has passed. The question is no longer whether manufacturers must comply.
The question is whether they will use compliance as the starting point for a stronger global regulatory strategy.
Anuradha Gore
Anuradha Gore, a seasoned Senior Manager at Freyr, has 18+ years of experience in the biotechnology and medical device industry. She serves as a QMS Subject Matter Expert and is a certified LEAs Auditor for ISO 13485, ISO 9001, and MDSAP. She has extensive experience in planning strategies and implementing ISO 13485, ISO 9001, 21 CFR 820, and MDSAP across a diverse portfolio of medical devices, IVDs, and SaMD.
